Volume 23, Issue 3 - Non-Clinical Health Writing

Opportunities in veterinary writing

Author: Nicola M. A. Parry

Abstract

Download the full article

References

1. FDA.gov. Silver Spring (MD): FDA's drug review process. c2014 [cited 2014 Apr 26]. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm
2. FDA.gov. Silver Spring (MD): Animal drugs. c2012 [cited 2014 Apr 26]. Available from: http://www.fda.gov/AnimalVeterinary/ResourcesforYou/ucm268128.htm
3. FDA.gov. Silver Spring (MD): The new animal drug approval process. 2013 [cited 2014 Apr 26]. Available from: http://www.fdli.org/docs/default-document-library/boxer%E2%80%94fda-approval-fdli.pdf?sfvrsn=0
4. Hampshire VA. Regulatory issues surrounding the use of companion animals in clinical investigations, trials, and studies. ILAR J 2003;44:191–6.
5. Southern Regional Aquaculture Center. Investigational new animal drug (INAD) exemptions and the National INAD Program (NIP). c2012 [cited 2014 Apr 26]. Available from: https://srac.tamu.edu/index.cfm/getFactSheet/whichfactsheet/242/
6. FDA.gov. Silver Spring (MD): S6 addendum to preclinical safety evaluation of biotechnology-derived pharmaceuticals. c2012 [cited 2014 Apr 26]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194490.pdf
7. Veterinary Record: This week's issue. c2014 [cited 2014 Apr 26]. Available from: http://veterinaryrecord.bmj.com/content/174/7.toc.pdf
8. Andrieson S. Medical translation: what is it, and what can the medical writer do to improve its quality? AMWA J 2006;21:157–159.
9. Goebel-Lauth S. Medical writing for the veterinary pharmaceutical industry – specialists needed. TWS 2011;20:29–30.